SPRY — ARS Pharmaceuticals, Inc.

SPRY Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $84.3 million for the full year 2025, comprising:
  • U.S. Net Product Revenue: $72.2 million from neffy sales.
  • Collaboration Agreements: $9.7 million.
  • Supply Revenue: $2.4 million from international partners.
• R&D Expenses: $13.2 million, primarily for product development and clinical trials.
• SG&A Expenses: $230.1 million, reflecting significant investment in commercialization efforts.
• Gross to Net Retention: Low to mid-50% range, targeting around 50% at steady state.
• Cash Position: $245 million in cash and equivalents, providing a strong balance sheet for ongoing operations.

2. Strategic Updates and Business Highlights

• Product Launch: 2025 marked the first full year of neffy as a commercial product, focusing on infrastructure and market education.
• Market Engagement: Over 22,500 healthcare providers prescribed neffy, with 50% being repeat prescribers.
• Sales Force Expansion: Plans to increase the sales force from 106 to 150 representatives, funded through reallocating existing resources without increasing overall SG&A expenses.
• Digital Strategy: Enhanced virtual and digital initiatives, including the "Get neffy on Us" program, which currently accounts for about 10% of prescriptions.
• International Expansion: Regulatory approvals are being pursued in Europe, China, Japan, and Australia.

3. Forward Guidance and Outlook

• 2026 Focus: Emphasis on disciplined execution with priorities in access, adoption, and advancement of neffy.
• Market Dynamics: Expectation of increased refill contributions starting in late 2026 as the installed patient base matures.
• DTC Campaign: Continued investment in direct-to-consumer advertising, maintaining a budget of approximately $100 million for 2026.

4. Bad News, Challenges, or Points of Concern

• Market Dynamics: Growth has not followed a linear trajectory due to the established refill-driven nature of the epinephrine market, where legacy auto-injectors dominate.
• Prior Authorization Issues: Approximately 55% approval rate for prior authorizations, which can hinder prescribing momentum.
• Dependency on New Prescriptions: As a new entrant, neffy relies heavily on new prescriptions, which require more time and effort compared to refill prescriptions.
• Competitive Pressures: The need to compete against entrenched auto-injector products that benefit from established prescribing habits.

5. Notable Q&A Insights

• Inventory Management: The company is closely monitoring inventory dynamics, particularly as they approach the back-to-school season.
• Direct-to-Consumer Spend: Expected to remain consistent with 2025 levels, focusing on optimizing spend rather than increasing it.
• Get neffy Program: Currently contributing over 10% of prescriptions, with expectations for growth as awareness increases.
• Refill Dynamics: Anticipated increase in refill prescriptions starting in late 2026, with current prescriptions predominantly from new patients.
• Sales Force Funding: Expansion funded by reallocating resources from lower-yield areas such as market research and certain advertising initiatives.

Overall, ARS Pharmaceuticals is navigating the complexities of launching neffy in a competitive market while focusing on strategic growth and operational efficiency.